Additional file 3 of Association of admission neutrophil serine proteinases levels with the outcomes of acute ischemic stroke: a prospective cohort study

Additional file 3: Table S1. The performance of models with and without NSPs for identifying patients with unfavorable outcome at 3 months. Table S2. Bivariate correlation between neutrophil counts and neutrophil elastase (NE), cathepsin G (CTSG), as well as proteinase 3 (PR3) plasma concentrations in the subgroups. Table S3. The Youden index of neutrophils serine proteinases for identifying patients with unfavorable outcome at 3 months in different groups. Table S4. Comparisons of dichotomous neutrophil elastase (NE), and proteinase 3 (PR3) levels according to the modified Rankin Scale (mRS) at 3 months in the whole study population (n = 342). Table S5. Logistic regression analysis and additional predictive value of the model including neutrophil elastase (NE) and proteinase 3 (PR3) concentration for patients with unfavorable outcome (mRS > 2) at 3 months in the subgroup of patients with available infarct volume (n = 212). Table S6. Comparisons of neutrophil serine proteinases plasma concentrations between patients eligible for IV recombinant tissue plasminogen activator (rtPA) or not. Table S7. Comparisons of neutrophil serine proteinases plasma concentrations between patients received bridging therapy or not. Table S8. Demographic and clinical data for the subgroup of patients received IV recombinant tissue plasminogen activator (rtPA) treatment (n = 119). Table S9. Comparison of dichotomous neutrophil elastase (NE) and proteinase 3 (PR3) levels in the subgroup of patients received rtPA treatment according to the modified Rankin Scale (mRS) at 3 months. Table S10. Correlation between neutrophil serine proteinases plasma concentrations and baseline characteristics in the whole study population (n = 342).